Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gritstone Oncology Inc (GRTS)
OTHER OTC:GRTS
Holding GRTS?
Track your performance easily
GRTS Stock Chart & Stats
Day’s Range$0.03 - $0.04
52-Week Range― - ―
Previous Close$0.05
Volume61.02M
Average Volume (3M)N/A
Market Cap
$2.30M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 07, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding118,109,074
10 Day Avg. Volume74,815,685
30 Day Avg. Volume35,138,353
Standard Deviation0.52
R-Squared0.00245
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.16
Price to Sales (P/S)47.99
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.75Price Target Upside5334.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Gritstone Oncology News
PremiumCompany Announcements
Gritstone Oncology Pursues Restructuring Through Chapter 11
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPhase 2 results for the GRANITE neoantigen program present a compelling near-term catalyst.
Financial PerformanceGritstone reported 2Q results slightly ahead of consensus estimates on lower-than-anticipated expenses.
Regulatory ApprovalThere is a 60% probability of approval in MSS-CRC, based on early signals of activity and the thoughtfulness of the EDGE platform.
Bears Say
Clinical TrialsThe latest update included only 69 out of the 104 enrolled patients as 35 patients dropped out of the study prior to treatment, which seems disproportionately high for this patient population.
Financial PerformanceShares were trading down as much as 40% after the proposed financing announcement.
Program DevelopmentGRTS’s SLATE off-the-shelf vaccine and CORAL infectious disease programs are both on pause while awaiting additional funding.
---
Ownership Overview
9.96% Insiders
8.33% Mutual Funds
0.06% Other Institutional Investors
74.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRTS FAQ
What was Gritstone Oncology Inc’s price range in the past 12 months?
Currently, no data Available
What is Gritstone Oncology Inc’s market cap?
Currently, no data Available
When is Gritstone Oncology Inc’s upcoming earnings report date?
Gritstone Oncology Inc’s upcoming earnings report date is Nov 07, 2024 which is 44 days ago.
How were Gritstone Oncology Inc’s earnings last quarter?
Gritstone Oncology Inc released its earnings results on Aug 13, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.274 by $0.114.
Is Gritstone Oncology Inc overvalued?
According to Wall Street analysts Gritstone Oncology Inc’s price is currently Undervalued.
Does Gritstone Oncology Inc pay dividends?
Gritstone Oncology Inc does not currently pay dividends.
What is Gritstone Oncology Inc’s EPS estimate?
Gritstone Oncology Inc’s EPS estimate is -$0.19.
How many shares outstanding does Gritstone Oncology Inc have?
Currently, no data Available
What happened to Gritstone Oncology Inc’s price movement after its last earnings report?
Gritstone Oncology Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.274. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gritstone Oncology Inc?
Among the largest hedge funds holding Gritstone Oncology Inc’s share is Versant Venture Management, LLC. It holds Gritstone Oncology Inc’s shares valued at 2M.
---
Gritstone Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.75 (5334.78% Upside)
$1.75 (5334.78% Upside)
Blogger Sentiment
Bullish
GRTS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.5%
Last 30 Days ▼ 9.9%
Last 30 Days ▼ 9.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.00%
12-Months-Change
Fundamentals
Return on Equity
-201.94%
Trailing 12-Months
Asset Growth
-35.97%
Trailing 12-Months
Company Description
Gritstone Oncology Inc
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
---
GRTS Company Deck
---
GRTS Earnings Call
Q1 2024
0:00 / 0:00
---
GRTS Stock 12 Month Forecast
Average Price Target
$1.75
▲(5334.78% Upside)
Technical Analysis
Best Analysts Covering GRTS
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-8.89%
reiterated a buy rating 3 months ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -8.89% per trade.
---